Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ALNY

ALNY - Alnylam Pharmaceuticals Inc Stock Price, Fair Value and News

$297.76+5.60 (+1.92%)
Market Closed as of 09 Jun 2026, 04:00 pm ET

72/100

ALNY

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

72/100

ALNY

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

ALNY Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ALNY Price Action

Last 7 days

4.1%

Last 30 days

0.9%

Last 90 days

-7.1%

Trailing 12 Months

-2.1%

ALNY RSI Chart

ALNY Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ALNY Valuation

Market Cap

39.7B

Price/Earnings (Trailing)

76.39

Price/Sales (Trailing)

9.27

EV/EBITDA

47.64

Price/Free Cashflow

61.76

ALNY Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

ALNY Fundamentals

ALNY Revenue

Revenue (TTM)

4.3B

Rev. Growth (Yr)

96.43%

Rev. Growth (Qtr)

6.39%

ALNY Earnings

Earnings (TTM)

520.2M

Earnings Growth (Yr)

1.2K%

Earnings Growth (Qtr)

59.23%

ALNY Profitability

EBT Margin

12.35%

Return on Equity

48.37%

Return on Assets

10.14%

Free Cashflow Yield

1.62%

ALNY Investor Care

Shares Dilution (1Y)

2.91%

Diluted EPS (TTM)

3.82

ALNY Alerts

  • 1 major insider sales recently.
  • Big jump in Revenue (Y/Y)
  • Big jump in Earnings (Y/Y)

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20264.3B000
20252.3B2.5B3.2B3.7B
20242.0B2.3B2.1B2.2B
20231.1B1.2B1.7B1.8B
2022880.0M884.2M960.9M1.0B
2021570.9M687.5M749.3M844.3M
2020285.9M345.2M401.0M492.9M
201986.3M101.1M169.1M219.8M
201892.9M106.8M91.8M74.9M
201764.3M78.1M93.0M89.9M
20166.7M7.1M7.7M47.2M
20153.2M4.2M5.0M5.9M
20141.2M1.6M2.1M2.6M
20131.0M1.0M1.0M1.1M
201258.2M39.1M20.1M977.0K
201196.4M0077.3M
2010000100.0M
Get all data in R, Python etc through our Historical Stock Data APIs

About Alnylam Pharmaceuticals Inc

ALNY
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITEalnylam.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES2002

Alnylam Pharmaceuticals Inc Frequently Asked Questions

ALNY is the stock ticker symbol of Alnylam Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Tue Jun 09 2026, market cap of Alnylam Pharmaceuticals Inc is 39.73 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Tue Jun 09 2026, ALNY's PE ratio (Price to Earnings) is 76.39 and Price to Sales (PS) ratio is 9.27. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ALNY PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Alnylam Pharmaceuticals Inc has provided 0.168 (multiply by 100 for percentage) rate of return.